Essential Omega 3 Fish Oil


(DEPA)



A rich source of long-chain omega-3 fatty acids

DESCRIPTION

DEPA, provided by Douglas Laboratories, contains a

marine lipid concentrate that has been processed by

molecular distillation. DEPA is an excellent source of

omega-3 fatty acids, providing eicosapentaenoic acid

(EPA, 18%) and docosahexaenoic acid (DHA, 12%)

in their natural triglyceride form

FUNCTIONS

Typical diets in developed countries deliver large

amounts of saturated fatty acids and the

polyunsaturated omega-6 linoleic and arachidonic

acids and low levels of omega-3 fatty acids.

Throughout evolution, humans were accustomed to

diets providing roughly equal amounts of omega-6

and omega-3 fatty acids. However, during the last

200 years, the ratio of dietary omega-6:omega-3 fatty

acids increased from about 1:1 to 20-25:1. Leading

health professionals now recommend ratios between

4:1 and 10:1.

A healthy balance of dietary omega-6 and omega-3

fatty acids appears to be a prerequisite for normal

immune function. Dietary linoleic acid (18:2 omega-

6) is a precursor to arachidonic acid (20:4) which in

turn is a precursor for pro-inflammatory

prostaglandin E2, leukotriene B4, and platelet

aggregating thromboxane A2. The omega-3 fatty

acids EPA and DHA provide a natural

counterbalance, because they serve as precursors for

the anti-inflammatory prostaglandins E1 and E3, and

decrease the formation of prostaglandin E2 and

thromboxane A2. Among other factors, sufficient

dietary levels of EPA, DHA and other omega-3 fatty

acids are also important in the regulation of normal

blood lipoprotein and cholesterol levels.

INDICATIONS

DEPA may be a useful dietary supplement for those

who do not consume enough oily fish and other

sources of omega-3 fatty acids in their diets to

receive desirable amounts of long chain omega-3

fatty acids.

FORMULA (#7980)

Each Softgel Capsule Contains:

Natural Triglyceride Marine

Lipid Concentrate ................................1,000 mg

Providing:

Eicosapentaenoic Acid (EPA) .....................180 mg

(18%)

Docosahexaenoic Acid (DHA) ....................120 mg

(12%)

Plus gelatin, natural glycerin and water

Total Omega-3 Fatty Acids .........................300 mg

Each Softgel Capsule Provides:

Calories.......................................................10.5

Protein ........................................... less than 0.5 g

Carbohydrates................................ less than 0.5 g

Fat (86% of calories from fat) .........................1 g

Polyunsaturated ............................................0.5 g

Saturated........................................ less than 0.5 g

Cholesterol.......................................................6 mg

SUGGESTED USE

Adults take 1 softgel daily or as directed by

physician.

SIDE EFFECTS

No adverse effects have been reported

STORAGE

Store in a cool, dry place, away from direct light.

Keep out of reach of children.

References

Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ,

Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of

sudden cardiac death [see comments]. Jama 1998;279:23-8.

Bougnoux P, Germain E, Chajes V, Hubert B, Lhuillery C, Le

Floch O, Body G, Calais G. Cytotoxic drugs efficacy correlates

with adipose tissue docosahexaenoic acid level in locally advanced

breast carcinoma. Br J Cancer 1999;79:1765-9.

Cerbone AM, Cirillo F, Coppola A, Rise P, Stragliotto E, Galli C,

Giordano M, Tremoli E, Di Minno G. Persistent impairment of

platelet aggregation following cessation of a short-course dietary

supplementation of moderate amounts of N-3 fatty acid ethyl

(continued on reverse)

Douglas Product Data

Laboratories®

esters. Thromb Haemost 1999;82:128-33.

Chin JP, Dart AM. HBPRCA Astra Award. Therapeutic restoration

of endothelial function in hypercholesterolaemic subjects: effect of

fish oils. Clin Exp Pharmacol Physiol 1994;21:749-55.

Chin JP, Dart AM. How do fish oils affect vascular function? Clin

Exp Pharmacol Physiol 1995;22:71-81.

Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart

rate variability and fatty acid content of blood cell membranes: a

dose-response study with n-3 fatty acids. Am J Clin Nutr

1999;70:331-7.

Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller J,

Rasmussen K, Dyerberg J, Schmidt EB. Effect of fish oil on heart

rate variability in survivors of myocardial infarction: a double

blind randomised controlled trial. Bmj 1996;312:677-8.

Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller

JM, Rasmussen K, Dyerberg J, Schmidt EB. [n-3 polyunsaturated

fatty acids, heart rate variability and ventricular arrhythmias in

post-AMI-patients. A clinical controlled trial]. Ugeskr Laeger

1997;159:5525-9.

Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K,

Dyerberg J, Schmidt EB. Fish consumption, n-3 fatty acids in cell

membranes, and heart rate variability in survivors of myocardial

infarction with left ventricular dysfunction. Am J Cardiol

1997;79:1670-3.

De Caterina R, Endres S, Kristensen SD, Schmidt EB. n-3 fatty

acids and renal diseases. Am J Kidney Dis 1994;24:397-415.

de Deckere EA, Korver O, Verschuren PM, Katan MB. Health

aspects of fish and n-3 polyunsaturated fatty acids from plant and

marine origin. Eur J Clin Nutr 1998;52:749-53.

Emken EA, Adlof RO, Duval SM, Nelson GJ. Effect of dietary

docosahexaenoic acid on desaturation and uptake in vivo of

isotope-labeled oleic, linoleic, and linolenic acids by male subjects

[In Process Citation]. Lipids 1999;34:785-91.

Endres S, De Caterina R, Schmidt EB, Kristensen SD. n-3

polyunsaturated fatty acids: update 1995. Eur J Clin Invest

1995;25:629-38.

Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid

(dha) [In Process Citation]. Pharmacol Res 1999;40:211-25.

Rice RD. Secondary prevention in acute myocardial infarction.

Clinicians must promote value of diet containing oil-rich fish

[letter]. Bmj 1998;317:1153-4.

Roche HM. Unsaturated fatty acids. Proc Nutr Soc 1999;58:397-401.

Simopoulos AP. Essential fatty acids in health and chronic disease.

Am J Clin Nutr 1999;70:560S-569S.

Spector AA. Essentiality of fatty acids. Lipids 1999;34:S1-3.

Supari F, Ungerer T, Harrison DG, Williams JK. Fish oil treatment

decreases superoxide anions in the myocardium and coronary

arteries of atherosclerotic monkeys. Circulation 1995;91:1123-8.

Takahata K, Monobe K, Tada M, Weber PC. The benefits and

risks of n-3 polyunsaturated fatty acids. Biosci Biotechnol

Biochem 1998;62:2079-85.

Tremoli E, Maderna P, Marangoni F, Colli S, Eligini S, Catalano I,

Angeli MT, Pazzucconi F, Gianfranceschi G, Davi G, et al.

Prolonged inhibition of platelet aggregation after n-3 fatty acid

ethyl ester ingestion by healthy volunteers. Am J Clin Nutr

1995;61:607-13.

Uauy R, Mena P, Valenzuela A. Essential fatty acids as

determinants of lipid requirements in infants, children and adults.

Eur J Clin Nutr 1999;53 Suppl 1:S66-77.

These statements have not been evaluated by the Food and Drug Administration.

This product is not intended to diagnose, treat, cure, or prevent any disease.

Manufactured by

Douglas Laboratories

600 Boyce Road

Pittsburgh, PA 15205